Compare CPSS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | TNXP |
|---|---|---|
| Founded | 1991 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.8M | 172.7M |
| IPO Year | 2010 | 2008 |
| Metric | CPSS | TNXP |
|---|---|---|
| Price | $7.78 | $12.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.1K | ★ 407.6K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.27 | ★ 91.75 |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $434,470,000.00 | $13,107,000.00 |
| Revenue This Year | $147.09 | $558.11 |
| Revenue Next Year | N/A | $38.29 |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | 10.41 | ★ 29.85 |
| 52 Week Low | $6.67 | $11.60 |
| 52 Week High | $10.39 | $69.65 |
| Indicator | CPSS | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 42.21 |
| Support Level | $7.38 | $11.60 |
| Resistance Level | $8.48 | $20.36 |
| Average True Range (ATR) | 0.25 | 1.13 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 15.29 | 24.03 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.